FDA deals a blow to GlaxoSmithKline's post-Advair hopes with Nucala COPD rebuff
admin 10th September 2018 Uncategorised 0Last week, GlaxoSmithKline used the tried-and-true technique of releasing bad news late on a Friday, when most people have checked out for the weekend. The disappointment? Its asthma drug Nucala, key to its respiratory strategy, got a thumbs-down from the FDA for a hoped-for new approval in chronic obstructive pulmonary disease.
More: FDA deals a blow to GlaxoSmithKline's post-Advair hopes with Nucala COPD rebuff
Source: fierce